PronoKal Health Science has begun its journey following the signing of the acquisition by new owners, Javier Sardiña and Dr. Ignacio Sajoux. Both, former executives of the previous company that owned the PronoKal brand, have launched a business plan backed by the Commercial Section of the Barcelona Court of First Instance, Plaza No. 3, and the insolvency administration, led by commercial lawyer and economist Jordi Adell (Crowe Legal y Tributario), after the company entered insolvency proceedings in February of this year.
The company’s new name reflects an approach to go beyond weight loss, directing the strategy to also address protein needs and supplementation for individuals, addressing overall health motivations.
Moreover, the two executives highlighted the three main strategic avenues for the company: “to adapt effectively to the real needs of the weight-control market, keep the physician at the center as the recommender, strengthening the scientific positioning, and accelerate technological innovation.” Within the latter area, AI tools and innovation will be strengthened, always preserving the value of the human team.
The presented business plan envisions optimizing the structure to enhance competitiveness and streamline internal processes, outsourcing non-critical functions and activities in order to focus on value creation and ensure the company’s sustainability. In this context, the modification will have no direct impact on the services or products offered.
Ensuring a Smooth and Stable Transition
Javier Sardiña, who assumes the role of Chief Executive Officer, has highlighted that, during the first weeks of activity for the new company, “the primary objective is to ensure a smooth and stable transition, from the structure and processes of the former company to the new organization.” Once this phase is completed, the implementation of the defined strategies for this new stage will begin to drive the evolution and sustained growth of the company. The objective is to progressively regain the pace of sales and close the year at an estimated €4.5 million (roughly $4.8 million at current rates), noting that the new company began billing in mid-May.
By the way, Dr. Ignacio Sajoux, Chief Innovation and Strategy Officer, said after the signing that one must leverage the value of a brand that has solidified its market presence through quality, its scientific foundation and its professionals during 22 years of activity, “but evolving and adapting to the market’s new dynamics with a more agile and flexible vision.”
The weight-management market has radically changed in recent years with the emergence of GLP-1 pharmacology. While PronoKal keeps its core focus on addressing overweight and obesity through a very low-fat ketogenic approach, its broad industry experience, multidisciplinary approach—including nutrition, exercise, and emotional support—and its extensive catalog of protein products aimed at preserving lean body mass become differentiating elements capable of adding value in this new landscape.
The team continuing the operation brings together professionals who were already part of the prior structure, with an average tenure of about 15 years, along with new profiles focused on daily operational management as well as strategy and sector specialization, aiming to meet future challenges.
It is estimated that nearly 6 million people in Spain actively seek health and wellness treatments focused on weight loss. With this new organization, PronoKal Health Science aims to establish itself as a benchmark for personalized solutions, offering everything from low-fat ketogenic diet programs to broader options featuring high-quality protein products and supplementation tailored to each individual’s needs.
